VPTDF - Ventripoint Remotely Installs Whole Heart Analysis System in Major European Hospital
(TheNewswire)
Toronto,Ontario -TheNewswire - September 28, 2020 - Ventripoint Diagnostics Ltd. (" Ventripoint " or the " Company "), (TSXV:VPT ) ( OTC:VPTDF) is pleased toannounce that it has remotely installed the latest version of itswhole-heart analysis system (VMS+3.0) in a Erasmus-Sophia UniversityMedical Center (Erasmus MC) in Rotterdam. This is the first time inthe Company's history, a system has become operational without aninstallation team going to the hospital to integrate it intohospital's infrastructure. It is also the first VMS+3.0 unit whichhas been placed in Europe.
"We have spent many months on akey initiative of adapting the VMS+3.0 to be an out-of-the-box productwith immediate activation and minimal customer requirements to lowerthe barrier for adoption and accelerate the sales cycle," statedDr. George Adams, CEO and Executive Chairman of Ventripoint. "Theinstallation went smoothly and only took a couple of hours withminimal hospital assistance."
A key modification of theVMS+3.0 was to make it self-contained system to eliminate need forinternet connection and improve security. Healthcare providers are becoming more andmore concerned about internet connections and cybersecurity. Theprevious model had a centralized server, which received the data(coordinates of the anatomical landmarks) over the internet andperformed the analysis and sent back the result. This model wasbecoming a significant barrier to adoption in this era of heightenedcyber-risks. Accordingly, the Company elected to encrypt thecatalogues and analysis software into the VMS+3.0. This change allowed thedevices to be self-contained and function completely inside thehospital using the internal PACS(archive) to store and retrieve echocardiograms and the resultantanalysis. This change has reduced the time to have the IT departmentsapprove the purchase of the VMS+3.0 as well as greatly simplified theinstallation procedure, such that it can now be done remotely withlittle assistance from the hospital staff.
An added benefit is the cost and timesavings for the Company, which now has shut down its analysis serverand transitioned users to the new stand-alone system. This will alsoallow sales in areas where the internet is not available orunreliable, such as much of the developing countries, where ultrasoundmachines are the only available imaging modality for cardiacdiagnosis.
Europe is expected to command thelargest share of the ultrasound market in future years according to aleading market research group with 2D ultrasound continuing to be thelargest segment ( https://www.marketsandmarkets.com/Market-Reports/ultrasound-market-467.html ).
The Company estimates that 40,000VMS+3.0 units would be required to diagnose and monitor patients withhearts conditions due to congenital heart disease, pulmonaryhypertension and cancer in North America and Europe. Additional unitswould be required for the rest of the world and for other patientpopulations such as COVID.
About Erasmus-SophiaUniversity Medical Centre
The Erasmus MC ranks #1 of the topEuropean institution in clinical medicine and #20 in the worldaccording to the Times HigherEducation rankings. The cardiology department isinvolved in teaching, research and treatment of cardiovasculardiseases with 5 focus areas: ischemic cardiovascular disease,congenital or acquired structural heart defects, arrhythmias and heartfailure.
About VentripointDiagnostics Ltd.
Ventripoint has become an industry leader in theapplication of AI (Artificial Intelligence) to echocardiography.Ventripoint's VMS products are powered by its proprietary KBRtechnology, which is the result of a decade of development andprovides accurate volumetric cardiac measurements equivalent to MRI.This affordable, gold-standard alternative allows cardiologistsgreater confidence in the management of their patients. Providingbetter care to patients serves as a springboard and basic standard forall of Ventripoint's products that guide our future developments. Inaddition, VMS+ is versatile and can be used with all ultrasoundsystems from any vendor supported by regulatory market approvals inthe U.S., Europe and Canada.
For further information, please contact:
Mr . Peter Weichler, Director
Email :peter@weichler.ca
Or
Mr. Clay Chase
Email: cc@sdthc.com
Phone: 858-456-7300
Neither the TSX Venture Exchange norits Regulation Services Provider (as that term is defined in thepolicies of the TSX Venture Exchange) accepts responsibility for theadequacy or accuracy of this news release.
Forward Looking Statements
This news release containsforward-looking statements and forward-looking information within themeaning of applicable securities laws. The use of any of the words"expect", "anticipate", "continue","estimate", "objective", "ongoing","may", "will", "project","should", "believe", "plans","intends'' and similar expressions are intended to identifyforward-looking information or statements. The forward-lookingstatements and information are based on certain key expectations andassumptions made by the Company. Although the Company believes thatthe expectations and assumptions on which such forward-look ingstatements and information are based are reasonable, undue relianceshould not be placed on the forward-looking statements and informationbecause the Company can give no assurance that they will prove to becorrect.
Since forward-looking statements andinformation address future events and conditions, by their very naturethey involve inherent risks and uncertainties. Actual results coulddiffer materially from those currently anticipated due to a number offactors and risks. Factors which could materially affect suchforward-looking information are described in the risk factors in theCompany's most recent annual management's discussion and analysis thatis available on the Company's profile on SEDAR at www.sedar.com. Readers are cautioned that the foregoinglist of factors is not exhaustive. The forward-looking statementsincluded in this news release are expressly qualified by thiscautionary statement. The forward-looking statements and informationcontained in this news release are made as of the date hereof and theCompany undertakes no obligation to update publicly or revise anyforward-looking statements or information, whether as a result of newinformation, future events or otherwise, unless so required byapplicable securities laws.
Copyright (c) 2020 TheNewswire - All rights reserved.